Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for enteroviruses ...

RNA drugs are a new type of medicine that treat disease by influencing how cells use genetic information, rather than by ...